



## **IMAGION BIOSYSTEMS LIMITED**

(ASX: IBX)

11 May 2020

### ***Imagion appoints new Non-Executive Director***

MELBOURNE — Imagination Biosystems Limited (ASX: IBX) (the **Company**), a company dedicated to improving healthcare through the earlier detection of cancer, today announced the appointment of Ms Dianne Angus to the Board of Directors. Ms Angus joined the Board as a Non-Executive Director with the appointment effective Friday, 8<sup>th</sup> May 2020.

Ms Angus brings to bear executive managerial and company director experience in the biotechnology, biopharmaceutical, agritech and healthcare industries, including practical experience in innovation curation, asset development and commercialization. With eighteen years' experience in ASX and NASDAQ-listed companies, including Neuren Pharmaceuticals and Prana Biotechnology (now Alterity Therapeutics), Dianne has strong stakeholder relations, corporate governance and compliance expertise as well as a track record in capital raising and corporate strategy.

Additionally, Dianne holds a Masters of Biotechnology, Bachelor of Science (Hons), and a Graduate Diploma of Intellectual Property (IP) Law. She is a registered patent attorney and a member of Australian Institute of Company Directors (AICD).

"I am delighted to join the Imagination Biosystems Board as the Company looks to transition its unique technology platform through clinical validation to demonstrate precise and early cancer detection. The MagSense™ technology has strong credentials to change clinical practice, deliver better patient outcomes and commercial success", said Ms Angus.

Bob Proulx, Executive Chairman of Imagination Biosystems said, "We are extremely pleased to welcome Dianne as a fellow director of Imagination. Dianne's successful track record as both a front line executive and an independent Director will be valuable to Imagination moving forward as we continue the development of and plan for the commercialization of our MagSense™ technology."

**-ENDS**

#### **About Imagination Biosystems**

Imagination Biosystems is developing a new non-radioactive and safe diagnostic imaging technology. Combining biotechnology and nanotechnology the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible. Imagination Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.

**This Announcement has been approved by the Disclosure Committee of Imagination Biosystems Limited**

For further information please visit [www.imaginationbiosystems.com](http://www.imaginationbiosystems.com)

#### **U.S. Media Contact:**

Matthew Wygant  
[matthew@biotechwriting.com](mailto:matthew@biotechwriting.com)  
+1-408-905-7630

#### **Australian Media & Investor Relations:**

Kyahn Williamson, WE Communications  
[We-AUImaginationBiosystems@we-worldwide.com](mailto:We-AUImaginationBiosystems@we-worldwide.com)  
+61-3-9866-4722

#### **Imagination Biosystems Limited**

ACN 616 305 027  
Level 25, 525 Collins Street, Melbourne VIC 3000  
[www.imaginationbiosystems.com](http://www.imaginationbiosystems.com)